45 Papers
364 Citations
P. Mathurin is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Alcoholic hepatitis & Cohort. The author has an hindex of 11, co-authored 40 publications. Previous affiliations of P. Mathurin include university of lille.
Chat about Author
Papers
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Antoine Hollebecque,S. Cattan,Olivier Romano,Géraldine Sergent,Abbas Mourad,Alexandre Louvet,Sébastien Dharancy,Emmanuel Boleslawski,Stéphanie Truant,F.-R. Pruvot,Mohamed Hebbar,Olivier Ernst,P. Mathurin +12 more
TL;DR: Aliment Pharmacol Ther 2011; 34: 1193–1201; http://dx.doi.org/10.1371/journal.pcap.1193.
111
Integrated Multiomics Reveals Glucose Use Reprogramming and Identifies a Novel Hexokinase in Alcoholic Hepatitis.
Veronica Massey,Austin Parrish,Josepmaria Argemi,Josepmaria Argemi,Montserrat Moreno,Aline Mello,Mar García-Rocha,José Altamirano,Gemma Odena,Laurent Dubuquoy,Alexandre Louvet,Carlos Prieto Martinez,Anna Adrover,Silvia Affò,Oriol Morales-Ibanez,Pau Sancho-Bru,Cristina Millán,Edilmar Alvarado-Tapias,Dalia Morales-Arraez,Juan Caballería,Jelena Mann,Sheng Cao,Zhaoli Sun,Vijay H. Shah,Andrew M. Cameron,P. Mathurin,Natasha T. Snider,Càndid Villanueva,Timothy R. Morgan,Joan J. Guinovart,Rajanikanth Vadigepalli,Ramon Bataller,Ramon Bataller +32 more
TL;DR: Altered metabolite levels and mRNA expression of metabolic enzymes suggest the existence of extensive reprogramming of glucose metabolism in AH, and increased HKDC1 expression may contribute to dysregulated glucose metabolism and represents a novel biomarker and therapeutic target for AH.
52
Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation
Antoine Hollebecque,Thomas Decaens,Emmanuel Boleslawski,P. Mathurin,Christophe Duvoux,F.-R. Pruvot,Sébastien Dharancy +6 more
TL;DR: In this paper, the authors present guidelines for therapeutic management of recurrent hepatocellular carcinoma (HCC) after liver transplantation, which are based on the natural history and appropriate diagnostic and management practices.
48
1094 100% svr in il28b cc patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the prove2 trial
Jean-Pierre Bronowicki,Christophe Hézode,Leif Bengtsson,Stanislas Pol,M. Bourlière,Lawrence Serfaty,V. de Ledinghen,Albert Tran,Yves Benhamou,Jean-Didier Grangé,P. Mathurin,Patrick Marcellin,C. Trepo,Jean-Pierre Zarski,S. Seepersaud,K. Kelliher,Martyn Botfield,J.-M. Pawlotsky +17 more
47
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*
Stanislas Pol,M. Bourlière,S. Lucier,V. de Ledinghen,Fabien Zoulim,C. Dorival-Mouly,S. Metivier,Dominique Larrey,Albert Tran,Christophe Hézode,Jean-Pierre Bronowicki,Didier Samuel,Didier Samuel,Patrick Marcellin,Jean-Pierre Zarski,Anne Minello,Laurent Alric,Jean-Claude Trinchet,P. Nahon,Dominique Guyader,Olivier Chazouillères,Ghassan Riachi,Véronique Loustaud-Ratti,Xavier Causse,P. Mathurin,I. Hubert-Fouchard,Isabelle Rosa,Yves Benhamou,J. Gournay,J.-J. Raabe,François Raffi,Ventzislava Petrov-Sanchez,Abou Diallo,Hélène Fontaine,Fabrice Carrat +34 more
41